Evidence map›Paper›PMID 26819270›Full record

ArticleInteractive cardiovascular and thoracic surgery2016

Prolyl-hydroxylase inhibitor activating hypoxia-inducible transcription factors reduce levels of transplant arteriosclerosis in a murine aortic allograft model.

Christian Heim, Wanja Bernhardt, Sabina Jalilova, Zhendi Wang, Benjamin Motsch, Martina Ramsperger-Gleixner, Nicolai Burzlaff, Michael Weyand, Kai-Uwe Eckardt, Stephan M Ensminger

Open access · bronzeAbstract read
In one paragraph

Article in Interactive cardiovascular and thoracic surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Christian HeimDepartment of Cardiac Surgery, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany christian.heim@uk-erlangen.de.
Wanja BernhardtDepartment of Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Sabina JalilovaDepartment of Cardiac Surgery, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Zhendi WangDepartment of Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Benjamin MotschDepartment of Cardiac Surgery, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Martina Ramsperger-GleixnerDepartment of Cardiac Surgery, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Nicolai BurzlaffDepartment of Chemistry and Pharmacy, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Michael WeyandDepartment of Cardiac Surgery, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Kai-Uwe EckardtDepartment of Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Stephan M EnsmingerDepartment of Cardiac Surgery, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany Present address: Heart and Diabetes Center NRW, Department of Thoracic and Cardiovascular Surgery, Ruhr-University Bochum, Bochum, Germany.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEHeart and Diabetes Center North Rhine-Westphalia · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe development of transplant arteriosclerosis, the hallmark feature of heart transplant rejection, is associated with a chronic immune response and also influenced by an initial injury to the graft through ischaemia and reperfusion. Hypoxia-inducible transcription factor (HIF)-1 pathway signalling has a protective effect against ischaemia-reperfusion injury and has already been demonstrated to ameliorate allograft nephropathy in previous animal studies. Therefore, the aim of this study was to investigate the effect of stabilization of hypoxia-inducible transcription factors with a prolyl-hydroxylase domain (PHD) inhibitor on transplant arteriosclerosis in an experimental aortic allograft model.

methodsMHC-class I mismatched C.B10-H2(b)/LilMcdJ donor thoracic aortas were heterotopically transplanted into the abdominal aorta of BALB/c mice. Donor animals received a single dose of the PHD inhibitor 2-(1-chloro-4-hydroxyisoquinoline-3-carboxamido) acetate (ICA) (40 mg/kg) or vehicle i.p. 4 h before transplantation. Intragraft HIF accumulation after ICA treatment was detected by immunohistochemistry before and after cold ischaemia (n = 5). Grafts were harvested 30 days after transplantation and analysed by histology (n = 7) and immunofluorescence (n = 7). In addition, intragraft mRNA expression for cytokines, adhesion molecules and growth factors was determined on Day 14 (n = 7).

resultsDonor preconditioning with ICA resulted in HIF accumulation in the aorta and induction of the HIF target genes vascular endothelial growth factor and transforming growth factor-beta. Vascular lesions were present in both experimental groups. However, there was significantly reduced intimal proliferation in preconditioned grafts when compared with vehicle controls [intimal proliferation 31.3 ± 8% (ICA) vs 55.3 ± 20% (control), P < 0.01]. In addition, experimental groups revealed a down-regulation of E-selectin (-57%) and MCP1 (-33%) expression after ICA pretreatment compared with controls, going along with decreased T-cell [1.4% CD4+ T-cell infiltration vs 8.4% (control) and 4.9% CD8+ T-cell infiltration vs 10.7% (control)], dendritic cell (0.6% dendritic cells infiltration vs 1.9% infiltration(control)] and macrophage infiltration [4.8% macrophages (ICA) vs 10.9% (control)] within vascular grafts.

conclusionsThese data of an animal transplant model show that the pharmaceutical activation of HIF with endogenous up-regulation of protective target genes leads to adaptation of the graft to low oxygen-saturation and hereby attenuates the development of transplant arteriosclerosis and allograft injury. Pharmaceutical inhibition of PHDs appears to be a very attractive strategy for organ preservation that deserves further clinical evaluation.

Indexed as

Gene Expression RegulationAllograftsAnimalsAorta, AbdominalArteriosclerosisDisease Models, AnimalHypoxia-Inducible Factor 1ImmunohistochemistryMiceMice, Inbred BALB CProlyl-Hydroxylase InhibitorsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTranscription FactorsHypoxia-Inducible Factor 1Prolyl-Hydroxylase InhibitorsRNA, MessengerTranscription FactorsHypoxia-inducible transcription factorsTransplant vasculopathy

Identifiers

PMID26819270
PMCPMC4892133
OpenAlexW2289468791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.